tbuckley/cabot-search huggingface dataset:
2371P Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)
Authors: S. Gupta, M.A. Climent Duran, S. Sridhar, T.B. Powles, J. Bellmunt, K. Tyroller, S. Guenther, A. di Pietro, P. Grivas
Journal: Annals of Oncology (2023)
The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the N Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer
Authors: James Huang, Raymond U. Osarogiagbon, Dorothy J. Giroux, Katherine K. Nishimura, Andrea Bille, Giuseppe Cardillo, Frank Detterbeck, Kemp Kernstine, Hong Kwan Kim, Yolande Lievens, Eric Lim, Edith Marom, Helmut Prosch, Paul Martin Putora, Ramon Rami-Porta, David Rice, Gaetano Rocco, Valerie W. Rusch, Isabelle Opitz, Francisco Suarez Vasquez, Paul Van Schil, Chi-Fu Jeffrey Yang, Hisao Asamura
Journal: Journal of Thoracic Oncology (2023)
2362MO Erdafitinib (erda) vs chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select FGFR alterations (FGFRalt): Subgroups from the phase III THOR study
Authors: Y. Loriot, N. Matsubara, R.A. Huddart, N. Houede, B. Laguerre, V. Guadalupi, J.H. Ku, S. Triantos, S. Akapame, K. Deprince, S. Mukhopadhyay, A.O. Siefker-Radtke
Journal: Annals of Oncology (2023)
2359O Phase III THOR study: Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (pts) with advanced or metastatic urothelial cancer (muc) with select fibroblast growth factor receptor alterations (FGFRalt)
Authors: A.O. Siefker-Radtke, N. Matsubara, S.H. Park, R.A. Huddart, E.F. Burgess, M. Ozguroglu, B. Perez Valderrama, S. Triantos, S. Akapame, Y. Kean, K. Deprince, S. Mukhopadhyay, Y. Loriot
Journal: Annals of Oncology (2023)
2223P Next-generation sequencing enables identification of RET rearrangements in papillary thyroid cancer
Authors: S. Clavé, M. Sese, R. Somoza, M. Arumí, C. Iglesias, J. Hernando, A. Garcia Alvarez, B. Lloveras, M. Guix Arnau, J. Capdevila Castillon, B. Bellosillo Paricio, J. Hernandez-Losa
Journal: Annals of Oncology (2023)
2224P Identifying prognostic factors in patients with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) treated with tyrosine kinase inhibitors (TKI): Data from REGETNE registry
Authors: M.V. San Roman Gil, J. Hernando, A.R. Granados, A. Carmona, G. Marquina Ospina, M.R. Bella, B. Castelo, S.E. Campos Ramirez, J. Molina Cerrillo, I. Ruz-Caracuel, P. Valderrabano, P. Luengo Pierrard, M. Roca Herrera, A. Garcia Alvarez, J. Pozas Perez, C. Gonzalez Merino, T. Alonso Gordoa, J. Capdevila Castillon
Journal: Annals of Oncology (2023)
2361MO Impact of positron emission tomography (PET) imaging on staging of muscle-invasive bladder cancer (MIBC) [PET-MUSE]
Authors: S. Sridhar, S.D. Mukherjee, N. Power, R. Breau, S. Cheng, P. Chung, G. Pond, U. Metser, M. Levine
Journal: Annals of Oncology (2023)
2363MO A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial, muscle invasive bladder cancer (ABACUS-2)
Authors: B.E. Szabados, E. Nogueron Martinez, F.J. Alvarez Marquez, D.E. Castellano Gauna, A. Rodriguez-Vida, M.C. Garcias de Espana, S.A. Hussain, C. Alvarez Fernandez, M. Linch, T. Bonfill Abella, M. Gross Goupil, J. Kelly, R.J. Jones, S. Crabb, L. Beltran, R. Garonce-Hediger, N.J. Rakebrandt, R. Georgescu, C. Ackerman, T.B. Powles
Journal: Annals of Oncology (2023)
2228P Long-term clinical outcomes of Lenvatinib in patients with differentiated thyroid cancer: Results from the real-world practice of a single institution
Authors: R. Onaga, T. Enokida, S. Okano, T. Fujisawa, H. Tanaka, N. Takeshita, N. Tanaka, Y. Hoshi, M. Tahara
Journal: Annals of Oncology (2023)
2360O The double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) as ≥ second-line therapy for metastatic urothelial carcinoma (mUC)
Authors: B.A. McGregor, G.P. Sonpavde, L. Kwak, X. Gao, C. Mantia, X.X. Wei, J.E. Berchuck, P. Ravi, M.D. Michaelson, T.K. Choueiri, J. Bellmunt
Journal: Annals of Oncology (2023)
2211MO Uncovering the mechanisms of persistent disease in RET-altered thyroid cancers: Insights from patient-derived xenograft models treated with selective RET inhibitors
Authors: A. Garcia Alvarez, J. Hernando, I. Chicote, J. Martínez-Quintanilla, A. Carmona, C. Iglesias, X. Serres Créixams, J. Jimenez, P.G. Nuciforo, S. Aguilar Izquierdo, J. Gonzalo, A. Vivancos, H.G. Palmer, J. Capdevila Castillon
Journal: Annals of Oncology (2023)
2221P Precision oncology in advanced thyroid carcinomas: Impact of molecular tests on patients’ outcomes
Authors: E. Colombo, S. Cavalieri, E. Tamborini, F. Perrone, B. Paolini, A. Ottini, F. Caspani, S. Buriolla, C. Bergamini, S. Alfieri, C. Resteghini, I. Nuzzolese, A. Vingiani, M. Duca, L. Agnelli, G. Pruneri, L.D. Locati, L.F.L. Licitra
Journal: Annals of Oncology (2023)
2182P Patient involvement to improve prospective follow-up: Quality of life data after cancer immunotherapy from the PRAISE study
Authors: E. Sebbag, J-E. Gottenberg, C. Chouaid, N. Cloarec, A. Najem, S.L. Rajpar, T. San, M. Porneuf, P. Barthelemy, C. Rizzo, L. Chauvenet, J. Meunier, A. Darut Jouve, S. Falkowski, J-F. Paitel, L. Geoffrois, S. Oudard, B. Braithwaite, N. Hamamouche, H. Servy
Journal: Annals of Oncology (2023)
2180P Detrimental effect of an early exposure to antibiotics on the outcomes of immunotherapy in a multi-tumor cohort of patients
Authors: V. Albarrán, J.J. Serrano, P. Sotoca-Rubio, A.M. Barrill Corpa, V. Alia Navarro, J. Moreno, J.C. Calvo, P. Pérez de Aguado, C. García de Quevedo, C. Gonzalez Merino, P. Guerrero, J. Pozas Perez, M.V. San Roman Gil, D.I. Rosero Rodriguez, J. Chamorro-Perez, P. Alvarez Ballesteros, F. Longo Muñoz, M.E. Olmedo Garcia, P. Garrido Lopez, P. Gajate Borau
Journal: Annals of Oncology (2023)
2212MO Major secondary outcomes in the multicentre noninferiority randomised trial IoN: Is ablative radioiodine necessary for low-risk differentiated thyroid cancer patients?
Authors: A. Hackshaw, K. Newbold, M. Beasley, K. Garcez, J. Wadsley, S. Johnson, T. Stephenson, M.N. Gaze, A. Goodman, S. Jeffries, D. Wilkinson, E. Macias, D. Power, T. Roques, L. Speed, G. Gerrard, S. Forsyth, E. Chang, K. Farnell, U.K. Mallick
Journal: Annals of Oncology (2023)
2175P Sex and age-related differences in immunotherapy-induced toxicities
Authors: M.T. da Costa, C. Lopes Fernandes, D. Silva, M.S. Pinho, A.A. Mesquita, F. Estevinho, M.L. Salgado, C. Sottomayor, H.I. Menezes Magalhaes
Journal: Annals of Oncology (2023)
2186P KN046 in patients with thymic carcinoma: A prospective, single-arm, multi-centre, phase II study
Authors: W. Fang, C. Wang, J. Li, M. Chen, Y. Ji, H. Fan, K. Wu, W. Zhuang, B. Liu, F. Luo, J. Shi, J. Wu, Y. Fang, Y. Zheng, X. Fu
Journal: Annals of Oncology (2023)
2177P Immunotherapy adverse events association with inflammation scores: A real-world data analysis from a Portuguese hospital
Authors: C.L. Fernandes, M. Teixeira da Costa, D.J. Silva, A.A. Mesquita, F. Estevinho, H.I. Menezes Magalhaes, M. Salgado, M.S. Pinho, C. Sottomayor
Journal: Annals of Oncology (2023)
2179P Prospective monitoring of autoimmune events in cancer immunotherapy patients: A report on the first 658 patients in the PRAISE study
Authors: E. Sebbag, N. Cloarec, I. Monnet, A. Najem, S.L. Rajpar, T. San, M. Porneuf, P. Barthelemy, C. Rizzo, J. Meunier, N. Hamamouche, H. Servy, G. Desjeux, C. Arnold, E-A. Sauleau, C. Chouaid, N. Sedmak, J-E. Gottenberg
Journal: Annals of Oncology (2023)
2220P MOLTHY project (TTCC-2020-02): A Spanish observational study for MOLecular characterization of THYroid carcinoma
Authors: N. Baste Rotllan, J. Hernando, J. Martínez Trufero, M. Plana Serrahima, J. Rubió-Casadevall, C. Álvarez-Escolá, E. Gallardo, C. Martinez-Vila, C. López López, T. Alonso-Gordoa, Á.A. Segura Huerta, A.J. Cunquero Tomás, A. García-Álvarez, E. Ortega Izquierdo, M. Oliva, C. Teixido, E. Sanfeliu Torres, M. Durán, C. Montalbán, R. Mesia
Journal: Annals of Oncology (2023)
2174P The impact of exposure to antibiotic (ATB) and proton pump inhibitor (PPI) therapy on immune checkpoint inhibitor (ICI) treatment on overall survival (OS): A population-based study
Authors: L. Eng, P.L. Bedard, R. Sutradhar, V. Aghanya, Y. Kaliwal, Y. Niu, N. Liu, Y. Liu, M. Powis, G. Liu, J. Peppercorn, S. Saibil, M.K. Krzyzanowska
Journal: Annals of Oncology (2023)
2149P Catheter-related thrombosis in cancer patients: Data from the registry of thrombosis and neoplasia of SEOM (TESEO)
Authors: F.J. Pelegrín Mateo, T. Quintanar Verduguez, D. Brilhante, A. Ferrández Arias, A.R. Cardozo, E. Martinez de Castro, J. Munoz-Langa, E.M. Brozos Vazquez, M. Biosca Gomez de Tejada, B.O. Portero, E. Gallardo Diaz, J. Rubio Perez, I. Fernandez Perez, I. Garcia Escobar, S. Garcia-Adrian, J.A. Santiago Crespo, L.R. Nogueira, G. Benitez Lopez, P. Jimenez Fonseca, A.J. Munoz Martin
Journal: Annals of Oncology (2023)
2148P Venous thromboembolism (VTE) in patients with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitors
Authors: L. Gervaso, C. Valenza, M. Mongillo, L. Boldrini, L. Boscolo Bielo, G. Castellano, L. Guidi, J. Katrini, E. Nicolo, G. Pellizzari, D. Trapani, C.A. Cella, I.T. Lorenzetti, S. Derio, M.T. La Presa, G. Parma, N. Fazio, G. Curigliano, A.A. Khorana, N. Colombo
Journal: Annals of Oncology (2023)
2146P Cancer-associated thrombosis clinic: Experience of the Medical Oncology Department of a hospital in Spain
Authors: L. Ortega Morán, J. Soto Alsar, R. Jiménez Rodríguez, C. López Jiménez, A. Gutierrez Ortiz, D.S. Juliao Caamaño, R. Martín Lozano, I. Gonzalez Caraballo, M. Palma, M.A. Cañete Muñoz, M. Benavente, B. Morón García, G. Torres Perez-Solero, M. Martin Jimenez, A.J. Munoz Martin
Journal: Annals of Oncology (2023)
2145P Thromboembolic disease associated with cyclin-dependent kinase inhibitors in patients with breast cancer
Authors: J. López Robles, E. Adoamnei, D. Cacho Lavin, C. Diaz PedRoche, E. Coma Salvans, M.I. Pamies Ramón, F.J.G. Verdejo, M. Cejuela, S. Garcia-Adrian, B.O. Portero, A. Garrido Fernandez, C. Salvador Coloma, J. Mendiola, A.J. Munoz Martin, M. Sanchez Canovas
Journal: Annals of Oncology (2023)
Meningococcal disease in the Middle East: A report from the Global Meningococcal Initiative
Authors: Seif S. Al-Abri, Musallam Yunus Abuhasan, Soha Shawqi A. Albayat, Xilian Bai, Hamad Bastaki, Ray Borrow, Dominique A. Caugant, Ghassan Dbaibo, Ala-Eddine Deghmane, Ener Cagri Dinleyici, Nedal Ghuneim, Mohamud Sheek-Hussein, Jay Lucidarme, Sean Leng, Maria G. Koliou, Marco A.P. Sáfadi, Jameela Al Salman, Tarek Al-Sanouri, Vinny Smith, Muhamed-Kheir Taha, Julio Vázquez, Claire Wright, Saber Yezli
Journal: Journal of Infection (2023)

This review details recent findings from the Global Meningococcal Initiative's (GMI) recent meeting on the surveillance and control strategies for invasive meningococcal disease in the Middle East. The nature of case reporting and notification varies across the region, with many countries using bacterial meningitis as an IMD case definition in lieu of meningitis and septicaemia. This may overlook a significant burden associated with IMD leading to underreporting or misreporting of the disease. Based on these current definitions, IMD reported incidence remains low across the region, with historical outbreaks mainly occurring due to the Hajj and Umrah mass gatherings. The use of case confirmation techniques also varies in Middle Eastern countries. While typical microbiological techniques, such as culture and Gram staining, are widely used for characterisation, polymerase chain reaction (PCR) testing is utilised in a small number of countries. PCR testing may be inaccessible for several reasons including sample transportation, cost, or a lack of laboratory expertise. These barriers, not exclusive to PCR use, may impact surveillance systems more broadly. Another concern throughout the region is potentially widespread ciprofloxacin resistance since its use for chemoprophylaxis remains high in many countries.
2150P Clinical and molecular characterisation of cancer-associated venous thromboembolism (VTE)
Authors: P. Mascaró Baselga, J.G. Yaringaño, P.B. Buch, P. Martínez-Albaladejo, A. de Torner, O. Mirallas, S. Eremiev, S. Serradell, J. Hernando, M. Roca Herrera
Journal: Annals of Oncology (2023)
2144P The PRognostic Oncologic Plantology (PROP) website tool predicts 30-day mortality in hospitalized cancer patients on treatment
Authors: O. Mirallas, B. Martin Cullell, V. Navarro, A. Pedrola, K.S. Vega Cano, J. Recuero-Borau, C. Salva, D.E. López Valbuena, D.A. Gomez Puerto, J. Sanz Beltran, J.M. Ucha Hermida, G. Molina Lores, M. Roca, A. Peñuelas Saiz, S. Serradell, J. Tabernero, S. Servitja Tormo, D. Paez, R. Dienstmann, J. Carles Galceran
Journal: Annals of Oncology (2023)
2142P Criteria for the choice of therapeutic ceiling in the hospitalized oncology patient: Healthcare impact of the multidisciplinary committee with the Intensive Care Unit (ICU)
Authors: M.E. Guirao García, M. Sanchez Canovas, A. Sanchez Saura, S. Montenegro Luis, M.A. Ivars, N. Blaya Boluda, N. Alonso Fernández, E. Martínez Quintana, M. Cerón García, L. López García, P.S. Bayoumy Delis, A. Carrillo Alcaraz, F. Ayala de la Pena
Journal: Annals of Oncology (2023)
2147P Thrombotic recurrence and bleeding complications in non-small cell lung carcinoma (NSCLC) patients with venous thromboembolism (VTE)
Authors: I. Gonzalez Caraballo, M.A. Cañete Muñoz, V. Velasco Durantez, M.E. Guirao García, P. Martinez del Prado, E. Segui Solis, R. Porta-Balanya, M. Covela, G. Benitez Lopez, M. Lobo de Mena, M.S. Moyano, H. Huertas, E. Martinez de Castro, E.M. Brozos Vazquez, T. Quintanar Verduguez, M. Biosca Gomez de Tejada, L. Ortega Morán, A. Carmona-Bayonas, P. Jimenez Fonseca, A.J. Munoz Martin
Journal: Annals of Oncology (2023)
2153P Circulating biomarkers to predict severe complications in cancer patients with low-risk chemotherapy-associated febrile neutropenia
Authors: S. Wikström Fernandez, A. Murillo Herrera, P. Garrido Ortega, L. García de Guadiana–Romualdo, P. Torrella Esteban, E. Feliciangeli
Journal: Annals of Oncology (2023)
2151P Incidence patterns and clinical implications of venous thromboembolism (VTE) in patients (pts) with neuroendocrine tumors (NET)
Authors: J. Hernando, M. Roca Herrera, A. Garcia Alvarez, S. Serradell, A. Garcia-Burillo, M.T. Salcedo, X. Molero, I. Navales, I. Diez, S. Landolfi, S. Castro, L. Blanco, X. Merino, G. Molina Lores, S. Vega, S. Bueno Salazar, J. Yaringaño, A. Carmona, S. Eremiev, J. Capdevila Castillon
Journal: Annals of Oncology (2023)
2084P Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Authors: I.B. Riaz, A. Ayaz, S.A.A. Naqvi, A. Bibi, K. Khakwani, Z.B. Riaz, U. Anjum, M. Khan, P. Singh, A.H. Bryce
Journal: Annals of Oncology (2023)
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance
Authors: Christina Yap, Jan Rekowski, Moreno Ursino, Olga Solovyeva, Dhrusti Patel, Munyaradzi Dimairo, Christopher J Weir, An-Wen Chan, Thomas Jaki, Adrian Mander, Thomas R Jeffry Evans, Richard Peck, Kathryn S Hayward, Melanie Calvert, Khadija Rerhou Rantell, Shing Lee, Andrew Kightley, Sally Hopewell, Deborah Ashby, Elizabeth Garrett-Mayer, John Isaacs, Robert Golub, Olga Kholmanskikh, Dawn P Richards, Oliver Boix, James Matcham, Lesley Seymour, S Percy Ivy, Lynley V Marshall, Antoine Hommais, Rong Liu, Yoshiya Tanaka, Jordan Berlin, Aude Espinasse, Johann de Bono
Journal: BMJ (2023)

SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2013 provides guidance for clinical trial protocol writing. However, neither the original guidance nor its extensions adequately cover the features of early phase dose-finding trials. The SPIRIT Dose-finding Extension (DEFINE) statement is a new guideline that provides recommendations for essential items that should be provided in the protocols of these trials. It details extensions to the SPIRIT 2013 guidance, incorporating 17 new items and modifying 15 existing items. The purpose of this guideline is to promote transparency, completeness, reproducibility of methods, and interpretation of early phase dose-finding trial protocols. It is envisioned that the resulting improvements in the design and conduct of early phase clinical trials will ultimately reduce research inefficiencies and inconsistencies, driving transformational advances in clinical care.
2091P Dermocosmetics in management of cancer-related skin toxicities: International expert consensus highlighting the key role of oncology nurses
Authors: P. Dielenseger, M. Lacouture, K. Khosrotehrani, G. De Barros Silva, J. Ryan Wolf, D. Kerob, M. Trombetta, E.O. Atenguena, M. Pan, F. Scotte, I. Krakowski, B. Dreno
Journal: Annals of Oncology (2023)
2119P The prognostic impact of nutritional assessment and scores in advanced gastric cancer
Authors: S. Torresan, M. De Scordilli, G. Bortolus, M. Bortolot, G. Zapelloni, R. Mazzeo, F. Totaro, G. De Pieri, C. Zanchetta, A. Michelotti, M. Casagrande, V. Fanotto, S.K. Garattini, G.G. Cardellino, N. Pella, D. Iacono, F. Puglisi, G. Fasola
Journal: Annals of Oncology (2023)
2094P A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer
Authors: S. Takada, D. Tsuji, T. Kawaguchi, T. Yokokawa, Y. Kawasaki, T. Yamaguchi, S. Tamaki, K. koizumi, T. Matsumoto, Y. Sakata, Y. Arakawa, H. Ayuhara, M. Yamaguchi, W. Suzuki, K-I. Watanabe, M. Hosonaga, S. Nakagaki, M. Hatori, M. Osawa, K. Suzuki
Journal: Annals of Oncology (2023)
2087P Impact of cancer pain on quality of life and financial well-being: A cross-sectional study on symptom management
Authors: R. Giusti, M. Filetti, P. Lombardi, G. Gentile, P. Toccaceli, G. Fumi, D. Vacca, E. Colpani, G. Ravoni, G. Daniele, G. Porzio
Journal: Annals of Oncology (2023)
2114P Impact of comprehensive geriatric assessment (CGA) in the management of chemotherapy toxicity in older cancer patients
Authors: J. Recuero-Borau, A. Gómez-Alderete, B. Areny, E-M. Amor, L. Rio, L. Visa Turmo, D. Conde-Estévez, M. Guix Arnau, M. Pi-Figueras
Journal: Annals of Oncology (2023)
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance
Authors: Christina Yap, Olga Solovyeva, Johann de Bono, Jan Rekowski, Dhrusti Patel, Thomas Jaki, Adrian Mander, Thomas R Jeffry Evans, Richard Peck, Kathryn S Hayward, Sally Hopewell, Moreno Ursino, Khadija Rerhou Rantell, Melanie Calvert, Shing Lee, Andrew Kightley, Deborah Ashby, An-Wen Chan, Elizabeth Garrett-Mayer, John D Isaacs, Robert Golub, Olga Kholmanskikh, Dawn Richards, Oliver Boix, James Matcham, Lesley Seymour, S Percy Ivy, Lynley V Marshall, Antoine Hommais, Rong Liu, Yoshiya Tanaka, Jordan Berlin, Aude Espinasse, Munyaradzi Dimairo, Christopher J Weir
Journal: BMJ (2023)

The CONSORT (CONsolidated Standards Of Reporting Trials) 2010 statement is the standard guideline for reporting completed randomised trials. The CONSORT Dose-finding Extension (DEFINE) extends the guidance (with 21 new items and 19 modified items) to early phase dose-finding trials with interim dose escalation or de-escalation strategies. Such trials generally focus on safety, tolerability, activity, and recommending dosing and scheduling regimens for further clinical development. These trials are often inadequately reported, hampering their informativeness and making evidence informed decisions difficult. The CONSORT-DEFINE guidance aims to develop an international, consensus driven guideline for reporting early phase dose-finding trials to promote transparency, completeness, reproducibility, and facilitate the interpretation of the results. The CONSORT-DEFINE guidance provides recommendations for essential items that should be reported in early phase dose-finding trials to promote greater clarity, reproducibility, informativeness, and usefulness of results.
2122P Clinical significance of oncology patients’ nutritional status assessment
Authors: E.P. Kostaridis, A. Michas, K. Gkikas, E. Arvanitou, A. Pouliakis, A. Tsitsimpis, M. Chantzipavlou, P. Xantzaridis, E. Panagou, X. Kagaras, I. Binas, M. Gkiaouraki, E. Stamatogianni, K. Ballasis, C. Christofyllakis, N.G. Tsoukalas
Journal: Annals of Oncology (2023)
2128P exerCise discussion with Oncologist duriNg caNcEr ConsultaTion: The CONNECT study
Authors: S. Pilotto, L. Belluomini, D. Tregnago, I. Trestini, M. Sposito, J. Insolda, L. Landi, S. Carnio, S. Vallone, V. Longo, D. Bafunno, D. Galetta, S. Ricciardi, M.R. Migliorino, S. Mariotti, M. Milella, S. Novello, A. Avancini
Journal: Annals of Oncology (2023)
2090P Management of trastuzumab deruxtecan-related nausea and vomiting in real-world practice
Authors: L. Licata, G. Notini, L. Sica, G. Viale, S. Zambelli, A. Rognone, D. Aldrighetti, M. Piras, A. Nuccio, P. Zucchinelli, G. Bianchini
Journal: Annals of Oncology (2023)
2117P Dietary patterns and clinical outcomes in patients with lung cancer: What needs to change
Authors: I. Borchardt, C. Augusto, E. Vieira, S. Chek, G. Farias, G.F. Moreira, F.C. Dias, F.T. Taveira, T.C. Montella, A.C. de Melo, W. Peres, C.G.M. Ferreira
Journal: Annals of Oncology (2023)
2088P Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists
Authors: A.A. Valsecchi, V. Fusco, M. Di Maio, D. Santini, M. Tucci, U.F.F. De Giorgi, R. Dionisio, F. Vignani, S. Cinieri
Journal: Annals of Oncology (2023)
2124P The impact of NUTRItional status at first medical oncology visit ON Clinical Outcomes: The NUTRIONCO study
Authors: M. Muscaritoli, A. Modena, M. Valerio, P. Marchetti, R. Magarotto, S. Quadrini, F. Narducci, G. Tonini, T. Grassani, L. Cavanna, C. Di Nunzio, C. Citterio, M. Occelli, A. Strippoli, B. Chiurazzi, A. Frassoldati, G. Altavilla, A. Lucenti, F. Nicolis, S. Gori
Journal: Annals of Oncology (2023)
2123P Value of immuno-nutritional scores in the prognosis of hospitalised patients with lung cancer
Authors: J.P. López, D. Jiménez Bou, I. Ruiz-Gutiérrez, L. Gutierrez Sainz, C. Navas-Jiménez, J.I. Alonso-Eiras, Á. García-Zamarriego, D. Sanchez Cabrero, L. Ruiz Jimenez Ubeda, A. Pertejo, J.P. Perez Wert, A. Alonso-Babarro, P. Cruz Castellanos, O. Higuera Gomez, J. de Castro Carpeño
Journal: Annals of Oncology (2023)
2125P Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study
Authors: A. Cortellini, A. Leonetti, A. Parisi, M. Tiseo, P. Bordi, M. Michiara, S. bui, A. Cosenza, L. Ferri, G.C. Giudice, I. Testi, B. Vincenzi, V. Santo, V. Ricozzi, P. Sgargi, F. Zustovich, L.S. Stucci, D. Santini, S. Buti, M. Bersanelli
Journal: Annals of Oncology (2023)
2115P Pre-cachexia incidence in patients with solid cancer: A cross-sectional study
Authors: L. Gottmann, L. Berchtold, M. Mair, A.M. Starzer, J.H. Fürst, J.M. Berger, C. Englisch, M. Kleinberger, M. Korpan, E. Hütterer, E.S. Bergen, M. Preusser, A.S. Berghoff
Journal: Annals of Oncology (2023)
2097P Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Authors: F. Manfredi, E. Sammarco, M. Ferrari, C. Mercinelli, A. Salfi, A. Bonato, G. Dima, D. Serafin, L. Zatteri, A. Antonuzzo, L. Galli
Journal: Annals of Oncology (2023)
2113P Efficacy and effectiveness of prophylactic magnesium supplementation on prevention of cisplatin-induced nephrotoxicity: A systematic review and meta-analysis
Authors: C.E.D.R. Castro, F. Dias, M.I. Dacoregio, I.F. Michelon, C.E. Stecca, M. Silveira Vilbert
Journal: Annals of Oncology (2023)
2105P Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Authors: R. De Sanctis, P. Tiberio, F. Jacobs, M. Gaudio, C. Benvenuti, A. Zambelli, C. Pozzi, G. Penna, A. Santoro, M. Rescigno
Journal: Annals of Oncology (2023)